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ABSTRACT

Triple negative breast cancer (TNBC) is a highly aggressive cancer, which is
known for a high rate of metastasis and poor prognosis. TNBC cells are hypothesized to
undergo the cellular processes epithelial-to-mesenchymal transition (EMT) and
mesenchymal-to-epithelial transition (MET). The known prognostic markers CD44+ and
Ki67 as well as the transcription factor and proposed tumor suppressor FoxO3a are
thought to be indicators of EMT and MET activity in cancer cells. In order to better
understand these processes an effective cell culture technique to mimic the tumor
environment needs to be established. The purpose of this study was to determine if
changing the cell culture environment would impact the expression of CD44+, Ki67 and
FoxO3a in TNBC cells.
The three TNBC cell lines BT-549, MDA-MB-157, and MDA-MB-231 were
cultured in either a monolayer (2D) environment or in Matrigel (3D). FoxO3a was
knocked down using siRNA to in MDA-MB-231 cells. The cells were
immunofluorescently stained to measure the intensity of CD44+, KI67, and FoxO3a
expression in both the 2D and 3D cell culture environment. Proliferation and wound
healing assays were performed to determine the proliferation and migration of MDAMB-231 cells.
The results indicate the expression of FoxO3a had significantly increased
(P<0.050) in cells cultured in a 3D environment. In the siRNA treated cells there was not
a significant difference in the expression of FoxO3a between cell culture environments.
The proliferation assay demonstrated cell culture environment does not have an effect on
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the proliferation of MDA-MB-231 cells. The migration assay proved MDA-MB-231 will
fill in a wound area over time.
The results suggest culturing cells in a 3D environment could have an impact on
cellular activity. Further studies need to be conducted to determine if this type of culture
environment could impact the EMT and MET activity of cancer cells and if FoxO3a
plays a role in these cellular processes as well.
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CHAPTER ONE
INTRODUCTION

Breast cancer is the second leading cause of death in women and accounts for
nearly 1 in 3 cancers diagnosed in women in the US. (DeSantis, et al., 2011). Of the
breast cancers cases being diagnosed, about 10-20% are the highly aggressive triple
negative breast cancer (TNBC). This particular type of breast cancer is associated with
poor prognosis and a high occurrence of metastasis. TNBC lacks the three receptors
estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) that are
often used in identification and treatment of other breast cancers. Traditionally, the cell
lines that lacked these receptors and that were grouped into the TNBC classification were
thought to share similar characteristics. However, recent evidence depicts this group of
cancer cells as exhibiting high heterogeneity, thus creating a varying number of subtypes
within the TNBC family.
Some of these cell lines, for example MDA-MB-231, exhibit stem-like activity,
which is often linked to the cellular process EMT or epithelial-mesenchymal transition.
EMT is often associated with a poor prognosis in women with breast cancer (Dvorak, et
al., 2011). The mesenchymal-epithelial transition or MET is the reverse of EMT and is
hypothesized to occur in metastatic cells in order for the cells to rapidly proliferate and
produce tumors at secondary sites (Foroni, et al., 2012).
The known cancer prognostic markers CD44+ and Ki67 are hypothesized to be
biomarkers for EMT and MET respectively. CD44+ is a cell surface protein that when
expressed in cancer cells is implicated in tumor progression and migration (Zhang,

Chang, & Liu, 2013). Ki67 is a nuclear protein that when expressed in cancer is
associated with high proliferation and is used to determine a short-term prognosis and to
predict the relapse rate in women with TNBC (Zurrida, et al., 2013).
Another protein that has the potential to be used as a prognostic marker and
EMT/MET biomarker is the transcription factor FoxO3a. The role of FoxO3a in cancer
cells is still unknown. Active FoxO3a is thought to be a tumor suppressor because it
targets pro-apoptotic proteins and prevent growth of unhealthy cells. However, there is
new evidence that in invasive cancers reactivating FoxO3a actually induces of tumor
progression.
In order to better understand the above information and the respective roles in
TNBC, a reliable cell culture method must be available. There is an increasing amount of
evidence demonstrating that using a 3D cell culture method to mimic the in vivo tumor
environment may be more reflective of the true in vivo conditions than the traditional
monolayer or 2D method. The 3D cell culture method could better represent the behavior
of cells and mechanisms involved in tumor progression seen in vivo and therefore make
transitioning research from in vitro to in vivo studies attainable with less complications.
The aim of this research was to investigate the effects of growing TNBC cell lines
in a 2D or a 3D cell culture environment. The expression of CD44+, Ki67 and FoxO3a
were investigated to determine if cell culture environment affected the expression of
these proteins in TNBC cell lines. To better understand the role of FoxO3a in TNBC,
siRNA knockdown of FoxO3a was performed to determine if silencing FoxO3a could
affect the expression levels of CD44+ and Ki67 along with the effect of cell culture
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environment. The proliferation of TNBC cell was investigated to determine if cells
cultured in either a 2D or 3D cell had different proliferation rates over time. The
migration of TNBC cells over time also was investigated. The results of this research
could provide insight into the impact of using a cell culture method to mimic the tumor
microevironment and its impact on the expression of certain proteins. These results could
assist in determining the role of FoxO3a in TNBC. Furthermore, along with the impact
of cell culture environment, the results from the proliferation and migration studies could
provide insight into devising further studies for investigating the mechanisms of EMT
and MET.
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CHAPTER TWO
LITERATURE REVIEW

Cancer Overview
Cancer is one of the leading causes of death not only in the United States, but
worldwide, and rates continue to rise as life expectancy increases. Cancer is a broad term
that encompasses diseases characterized by unregulated cell growth and the ability to
evade the programmed cell death known as apoptosis. Mutations, alterations in
pathways, genes, and transcription factors, contribute to unregulated cell growth and
development. Certain individuals may be predisposed to different types of cancer due to
genetic mutations while others are put at risk due to various external factors including
diet, environment, infections and diseases.
When cells begin to grow uncontrollably they develop a mass referred to as a
tumor categorized as benign or malignant. Whether a tumor is malignant or not is
determined by its ability to invade other parts of the body outside of its area of origin.
“Accumulation of genetic alteration in proto-oncogenes, tumor suppressor genes and
DNA repair genes will push pre-malignant to malignant initiating primary tumor
formation” (Voulgari & Pintzas, 2009) at the site of origin. These rapidly growing cells
utilize the lymphatic system and blood stream to migrate to other parts of the body to
form secondary tumors. This process is referred to as metastasis. Metastatic tumor cells
acquire the ability to evade anchorage-dependent apoptosis, known as anoikis, in order to
survive as they migrate throughout the body (Voulgari & Pintzas, 2009).
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The different forms of cancers are named based on the particular type of tissue
cells from which they originate. These tissue cells include epithelial, connective, blood,
lymphatic, and in rare cases nervous tissue. Epithelial tissue lines all of the organs and
cavities of the body, the most prevalent form of cancer is of epithelial origin (Muranen, et
al., 2012). One particular cancer of epithelial origin is breast cancer.
Breast Cancer
Breast cancer is one of the more common malignant cancers among women
worldwide (DeSantis, et al., 2011; Ho-Yen, et al., 2012), with over 1 million new cases
per year (Ho-Yen, et al., 2012; Francken, et al., 2013). In the U.S. breast cancer accounts
for nearly 1 in 3 cancers diagnosed among women (DeSantis, et al., 2011). As a whole,
breast cancer is the second leading cause of death in women (DeSantis, et al., 2011) with
an estimated 120,000 deaths occurring annually in the U.S. and Europe combined (Prat &
Perou, 2011). Breast cancer occurrence and mortality rates are not uniform, but vary
among different ages, race, ethnicity, geographical location, and genetic predisposition.
For example, African American women have a lower incidence of breast cancer, but a
much higher mortality rate than other races (Swede, et al., 2011). Various factors
contribute to this high mortality rate including socioeconomics, clinical factors, and
biological behaviors (Swede, et al., 2011).
Healthy breast tissue consists of multiple types of cells and tissue including
epithelial cells, stromal cells, and lymphatic and blood vessels (Bosch, et al., 2010).
Myoepithelial, ductal epithelial, and alveolar epithelial cells are three of the types of
epithelial cells found in adult mammary glands, each with its own unique function at
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various stages of mammary development and function (Hwang-Verslues, et al., 2008).
These different types of epithelium are one of the many factors that may contribute to the
heterogeneity of breast cancer. This heterogeneity not only affects the type of treatment
to be used but the classification of the numerous subtypes that make up the breast cancer
family. Classification of breast cancer began by observing the presence or absence of
three hormone receptors in the cancer cells. The three hormone receptors that are used to
diagnose the different types of breast cancer are the estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2). These receptors
in healthy breast cells are essential for growth and function, but when over-expressed in
cancer their function becomes essential in growth, motility and maintenance of the tumor.
Breast cancer with an over-expression of one or more of the receptors is referred to as
receptor positive, while breast cancer cells that lack one or all of these receptors are
referred to as negative or receptor negative. Cells that lack the expression of all three of
these receptors are referred to as triple negative breast cancer (TNBC). This phenomenon
is why treatment for TNBC is more difficult because a majority of treatments for breast
cancer target the hormone receptors. About 60% of breast cancers are positive for
receptors while only about 15% are triple negative (Chen & Russo, 2009).
Triple Negative Breast Cancer
Triple negative breast cancers are biologically more aggressive than other forms
of breast cancer. TNBC tumors tend to be larger in size, have a higher diagnostic grade
and have lymph node involvement at diagnosis (Lehmann, et al., 2011). The
demographic TNBC usually affects is younger women, particularly African Americans
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and Latinos. The type of therapies and outcomes of patients with TNBC are variable
despite the stage and time of diagnosis (Bosch, et al., 2010). Due to the aggressive nature
of this class of breast cancer, patients with TNBC have a higher rate of metastasis, distant
recurrence and poorer prognosis (Lehmann, et al., 2011). The percentage of women with
metastatic TNBC who survive 5 years is less than 30%, and almost all will eventually die
from their disease despite treatment (Lehmann, et al., 2011).
It is thought that about 80% of TNBC arise from BRCA1 mutation (Chen &
Russo, 2009). Normally BRCA1 is involved in double stranded DNA repair for DNA
stability (Lehmann, et al., 2011) and is one of the genetic mutations that is often screened
in women diagnosed with breast cancer. Those with this genetic mutation have a higher
risk of developing breast cancer and the mutation can be heritable (Francken, et al.,
2013), however, not all TNBC cases are caused by BRCA1 mutations, and not all
BRCA1 mutations are triple negative. Until recently tumors with TNBC characteristics
were categorized into one large group, and all cell lines were treated in the same manner.
Recently, researchers began to realize, through gene expression studies that there are
various subtypes within the TNBC group, a fact which caused a re-examination of the
breast cancer classification as a whole (Ho-Yen, Bowen, & Jones, 2012; Lehmann, et al.,
2011). It was determined that there is an overlap between TNBC and other types of
breast cancer. One particular subgroup found in TNBC is referred to as basal-like. The
basal-like subgroup is characterized by over-expression of genes in basal epithelium.
This classification is different from the TNBC term because of molecular observations
rather than the clinical observation of the lack of hormone receptor staining (Bosch, et al.,
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2010). Terms share overlap, for example not all TNBC are basal-like and not all basallike are TNBC. It is estimated there is about a 30% discordance (Bosch, et al., 2010).
There is more of a histoclinical and molecular difference between basal-like and non
basal-like TNBC than between TNBC and non-TNBC. This suggests TNBC is more
heterogeneous than originally thought (Ho-Yen, Bowen, & Jones, 2012).
Other subgroups that have been identified thus far include luminal, basoluminal,
immunomodulatory, mesenchymal, and mesenchymal stem-like (Elsawaf, et al., 2013;
Lehmann, et al., 2011). Researchers have used various techniques including gene
expression profiling and cluster analysis to group the various cell lines. Some of these
groups share similar characteristics, but have features that make them distinct. For
example, a number of cell lines in the mesenchymal and mesemchymal stem like are
considered part of the basal subtype but have other characteristics that make them unique
(Lehmann, et al., 2011). The mesenchymal and mesenchymal stem like group express
both epithelial and mesenchymal components, and they share similar gene ontologies and
gene expression profiles involving signaling pathways that are often found in the
epithelial-mesenchymal transition (EMT), which play a role in cell motility and cancer
metastasis (Lehmann, et al., 2011). Some of these cell lines, mostly in the mesenchymal
stem like, express stem-like cancer cell characteristics (Lehmann, et al., 2011), but this
concept of stem cell activity in cancer cells is still very new and controversial (HwangVerslues, Chang, Lee, & Lee, 2008). Some examples of cell lines that are found in these
two subgroups include BT-549, MDA-MB-157, and one of the more frequently used
TNBC cell lines in breast cancer research MDA-MB-231. These cell lines are also
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grouped in the basal B subtype and in another recently discovered subtype referred to as
claudin-low (Prat & Perou, 2011). The claudin-low subtype shows stem-like features and
EMT signatures, but is currently being identified as to whether it is a true subtype or just
a characteristic (Prat & Perou, 2011) of a subgroup. These various subgroups allow for a
better understanding of the behavior of these different cell lines and bring researchers
closer to developing individualized treatments. Regardless of these new subtypes and
identification techniques, current diagnosis continues to rely on the traditional hormone
receptor based identification. Currently, hormone receptors are the simplest, fastest
method and are still a useful diagnostic tool.
EMT/MET and their Role in Cancer
Breast cancer cells that are metastatic are thought to go through a cellular process
referred to as the epithelial-mesenchymal transition (EMT) to make the cells highly
motile allowing for invasion into other tissue. The reverse of this process is referred to as
the mesenchymal-epithelial transition (MET) where cells lose motility and increase
proliferation. These processes are thought to be what drives the development of
secondary tumors. EMT is often associated with poor prognosis in women with breast
cancer (Dvorak, et al., 2011).
EMT was first recognized in the late 1970s as a distinct process (Tiwari, et al.,
2012). There are three known subtypes of EMT that occur at various stages of life and
each type has a distinct function. Type 1 is involved in embryonic implantation,
gastrulation, and neural crest motility during fetal development (Tiwari, et al., 2012).
Type 2 is involved in tissue regeneration, wound healing, inflammation and fibrosis
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(Tiwari, et al., 2012; Anwar & Kleer, 2013) while type 3 is involved in cancer
progression and metastasis (Anwar & Kleer, 2013). Knowledge about type 3 EMT is still
very limited (Tiwari, et al., 2012), but there is new evidence that breast cancer cells may
undergo a reactivation of the embryonic or type 1 EMT program to acquire traits for
invasion and metastasis (Foroni, et al., 2012). EMT is highly inducible in in vitro studies
with breast cancer cell lines, but EMT in vivo results are limited (Foroni, et al., 2012).
Researchers are skeptical about the existence of EMT and therefore current therapeutics
specifically targeting EMT do not yet exist (Tiwari, et al., 2012).
Epithelial cells are well-organized and display apico-basal polarity (Foroni, et al.,
2012). These cells are closely attached to a basement membrane and other cells with
tight junctions, cadherins and other adhesion molecules (Foroni, et al., 2012; Tiwari, et
al., 2012). The epithelial cells have a more uniform shape and have the ability to rapidly
proliferate (Tiwari, et al., 2012). EMT affects these epithelial characteristics in order to
transition the cells into mesenchymal cells. One of the more important occurrences
during EMT is that cells must detach from both the basement membrane and the
neighboring cells. One important adhesion molecule that is affected by EMT is Ecadherin. In healthy epithelial cells, E-cadherin acts as a repressor of tumor progression
by maintaining cell-cell contacts and preventing motility (Tiwari, et al., 2012). In
epithelial cancers, including breast cancer, E-cadherin is found to be inactive allowing
cells to migrate through tissues (Voulgari & Pintzas, 2009). Decreased E-cadherin has
been associated with cells expressing high levels of the cancer motility biomarker CD44+.
When E-cadherin activity decreases there is a switch to N-cadherin, which lacks the cell
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adhesion features necessary for cell-cell contacts (Voulgari & Pintzas, 2009). EMT
results in the reorganization of the extracellular matrix (ECM) by up-regulation of the
expression of various ECM proteins, proteases and other remodeling enzymes (Foroni, et
al., 2012). The reorganization allows for mesenchymal cancer cells to migrate through
the matrix and invade other tissues. Matrix metalloproteinases (MMP) are one of the
more studied mechanisms of ECM degradation and have been seen to promote
tumorigenesis (Voulgari & Pintzas, 2009). In healthy tissue, as the interactions between
the ECM and the epithelial cells are disrupted the anchorage dependent programmed cell
death, anoikis, is induced (Voulgari & Pintzas, 2009). Yet, a resistance to anoikis has
been shown to promote metastasis. One factor that promotes metastasis by inducing
anoikis resistance is the loss of E-cadherin in the beginning steps of EMT (Voulgari &
Pintzas, 2009). This resistance to anoikis is important to tumor cells during migration
because once these cells separate from the tumor mass it is necessary to survive without
the signaling cues from the tumor microenvironment (Tiwari, et al., 2012). The initiation
and maintenance of EMT is very complex and not completely understood but several
factors have been seen as essential to EMT. Some of these include growth factors, PI3K
signaling, transcription factors including snail 1 and 2, Twist, and a large number of
miRNAs (Tiwari, et al., 2012).
Once the epithelial cells become mesenchymal through EMT they exhibit
different characteristics such as reduced apico-basal polarity, high motility,
differentiation and low proliferation. Loss of apico-basal polarity allows for the cells to
acquire front-back polarity to allow for motility (Voulgari & Pintzas, 2009). Most of the
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available energy in these cells is used on motility and therefore proliferation activity and
other cellular processes are low. In distance metastasis EMT markers are often not
apparent (Foroni, et al., 2012). Distance metastasis occurs when tumor cells migrate
from the primary tumor site into the blood stream; the blood stream then carries them to
the secondary tumor location. It is believed at the secondary tumor site, that the cells
promptly undergo MET to shed their mesenchymal phenotype in order to be able to
proliferate and rapidly produce the secondary tumor (Foroni, et al., 2012). Not as much
is known about MET, but one factor may influence the microenvironment to which the
cells migrate (Foroni, et al., 2012). During MET the genes involved are being expressed
while at the same time the EMT genes are being suppressed (Ferrari, Nicolini, & Carpi,
2013). It is hypothesized that MET may induce cell death and make cancer cells more
sensitive to therapy, indicating that this process could be a beneficial target for the
development of new drugs for treating highly metastatic breast cancer including TNBC
(Foroni, et al., 2012). The existence of MET has received recent criticism, which may be
one of the reasons researchers have had difficulty proving the existence of EMT
(Voulgari & Pintzas, 2009).
CD44+ and Ki67
There are two known proteins, CD44+ and Ki67 that are used as prognostic
markers in TNBC and other cancers. They are hypothesized to be biomarkers of EMT
and MET.
CD44+
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CD44+ is a single chain glycoprotein that is located on the cell surface and is a
major receptor for hyaluronan (Zhang, Chang, & Liu, 2013). It mediates cell adhesion in
epithelial cells through interactions between cells as well as cell and matrix interactions
(Zhang, Chang, & Liu, 2013). In breast cancer, expression of isoforms of CD44+ have
prognostic value due to their implication in tumor progression and migration (Zhang,
Chang, & Liu, 2013). CD44+ has been proposed as a possible biomarker for putative
cancer stem cells (Zhang, Chang, & Liu, 2013). The expression of CD44+ in cancer cells
is often associated with high-grade tumors and a poor prognosis. Zang et al. investigated
the CD44+ expression in ovarian carcinoma and found in this particular cancer CD44+ is
not a prognostic predictor, but an identifier of advanced stage ovarian carcinoma. Often
times in cancer studies, expression of CD44+ is examined in correlation with CD24-/low.
Invasive breast cancer cell lines that exhibit a basal/mesenchymal phenotype have been
found to have a high proportion of CD44+/CD24-/low (Choi, et al., 2013). This goes along
with the idea that during EMT CD44+ is high. An article by Anwar et al discussed that
cells exhibiting CD44+/CD24-/low exhibited EMT markers including decreased E-cadherin
and up-regulation of EMT associated transcription factors (Anwar & Kleer, 2013).
TNBC, especially the basal-like arising from BRCA1 mutations, is often associated with
high CD44+/CD24-/low. This is a good indication of high metastatic potential in these cell
types (Anwar & Kleer, 2013). Metastasized breast cancer cells found in the bone marrow
have exhibited an increase in CD44+/CD24-/low, which helps in supporting the relationship
between metastasis and EMT (Chang & Mani, 2013). CD44+/CD24-/low cells are
considered to have stem/progenitor cell phenotype because not only do they express
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CD44+, but they have the ability to self-renew, differentiate, and proliferate (Idowu, et
al., 2012). In a study by Idowu et al., in 2011, demonstrated that the CD44+/CD24-/low
stem/progenitor cell phenotype is significantly associated with TNBC and exhibits an
increased risk of recurrence and metastasis (Idowu, et al., 2012).
Ki67
The second prognostic marker, Ki67, is a nuclear protein that is associated with
cell proliferation and transcription of ribosomal RNA (rRNA) (Tadbir, et al., 2012).
Inhibition of rRNA synthesis occurs when Ki67 is inactivated. Ki67 is present in all
active phases of the cell cycle except the resting cell stage, G0 (Tadbir, et al., 2012).
During mitosis Ki67 travels to the cell surface of the chromosomes but during interphase
it is exclusively in the nucleus of the cell (Tadbir, et al., 2012). Ki67 levels are used as a
method to determine short-term prognosis, and as a predictor for relapse rate in women
with TNBC (Zurrida, et al., 2013). Patients with high Ki67 have a low rate of distant free
survival (DFS) (Zurrida, et al., 2013). This was observed in a study by Zurrida et al.,
who examined Ki67 in early breast cancer patients with clinically clear axillary lymph
nodes and the subsequent effects of axillary radiotherapy. They found patients who did
not undergo axillary radiotherapy had significantly worse DFS and high Ki67, than in
those who received radiotherapy. “No other protein shows an expression pattern that is
equally tightly regulated in dependence to proliferative status of the cell” (Scholzen &
Gerdes, 2000). It has been presented there is a higher rate of proliferation in malignant
than benign tumor cells, which may explain why tumors with high expression of Ki67
have a high rate of recurrence (Tadbir, et al., 2012). Ki67 expression could be used as a
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marker for MET activity, due to the fact that Ki67 is a marker for cell proliferation. As
previously discussed, mesenchymal cells have low to no proliferation activity whereas
epithelial cells rapidly proliferate (Voulgari & Pintzas, 2009). Theoretically, as tumor
cells are going through MET the levels of Ki67 should be increasing. This not only
makes Ki67 a good prognostic marker, but a good marker for EMT/MET activity in
cancer cells.
FoxO3a Tumor Suppressor or Tumor Promoter
FoxO3a is one protein in particular that may have prognostic implications in
cancer cells, but has been shown to have conflicting roles in tumor progression. FoxO3a
is thought to be a tumor suppressor, but also has exhibited characteristics to drive
proliferation and migration in invasive cancers. It may play a role in the EMT/MET
cellular processes. Foxo3a is part of the large Forkhead box (Fox) family of transcription
factors (Reagan-Shaw & Ahmad, 2007). Of the 19 subgroups identified A to S in the Fox
family, FoxO3a belongs to the O subgroup and is one of four FoxOs currently identified.
Of the four, FoxO1, FoxO3 and FoxO4 are all ubiquitously expressed in mammals
(Zhang, et al., 2011). Also these three were found initially at chromosomal translocation
in tumors, which suggests they may play a role in tumor development (Reagan-Shaw &
Ahmad, 2007). FoxO3 can be referred to as FoxO3 or FoxO3a depending on the species.
In mice it is known as FoxO3, while in humans it is known as FoxO3a. FoxO3b is
referred to as a pseudogene meaning it is no longer present or active in the cells, while
FoxO3a is an active gene (Arden, 2006). The FoxO group, including FoxO3a, functions
to induce the transcription of pro-apoptotic genes (Tiwari, et al., 2012) that induce
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apoptosis during various times when needed (Dansen & Burgering, 2008). There are two
modes of cellular signaling that regulate the function of the FoxO group: insulin signaling
through the phosphotide-3-kinase (PI3K)/Akt pathway and cellular stress signaling,
especially oxygen stress (Dansen & Burgering, 2008). The insulin signaling and kinase
pathways inactivate FoxOs, whereas the stress signaling initially activates the FoxO
protein before inactivation (Dansen & Burgering, 2008). The initial activation during
stress is most likely to mediate stress resistance and to prevent premature cell death
(Dansen & Burgering, 2008). FoxO3a is inactivated by phosphorylation by kinases of
the Akt family, along with various growth factors (Dansen & Burgering, 2008).
Phosphorylation is not the only way for FoxO3a to lose its function; acetylation and
ubiquitination can also cause inactivation (Reagan-Shaw & Ahmad, 2007). FoxO3a’s
location within the cell depends primarily on this phosphorylation. When PI3K and Akt
pathways are inactive and growth factors are absent, FoxO3a is found in the nucleus
actively transcribing for cell cycle arrest and apoptosis (Reagan-Shaw & Ahmad, 2007).
When FoxO3a becomes phosphorylated it is translocated from the nucleus to the
cytoplasm (Reagan-Shaw & Ahmad, 2007). When in the cytoplasm, FoxO3a is inactive,
but this is not the end point of FoxO3a. Dephosphorylation of FoxO3a allows it to move
back into the nucleus and actively transcribe again (Zhang, et al., 2011).
In cancer, phosphorylation of FoxO3a is a crucial step in order for the cells to
evade apoptosis during tumorigenesis, which is why it is thought to be a tumor
suppressor. The disruption of normal Akt signaling is one of the more frequent
occurrences in a majority of cancers, including breast cancer. The PI3K pathway is
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activated by genetic abnormalities causing hyperactivation, which results in the
hyperactive downstream effect on Akt (Brugge, Hung, & Mills, 2007). Journal articles
discussing cancer and cell survival, identify the pathway as the PI3K/Akt pathway. PI3K
regulates cell survival, cell growth, proliferation, and migration (Brugge, Hung, & Mills,
2007). Akt promotes cell survival and phosphorylation of pro-apoptotic proteins and
drives proliferation. Due to the increase in PI3K/Akt activity, FoxO3a is commonly
phosphorylated and inactivated, which is one reason why FoxO3a activity could be a
prognostic and therapeutic target. A study conducted in breast cancer cells that knocked
down PI3K/Akt revealed that FoxO3a was significantly activated. The induction of
apoptosis and a decrease in cell viability (Reagan-Shaw & Ahmad, 2007) could have
resulted from the activation of FoxO3a. Another study investigated the possibility of
targeting FoxO3a as a possible treatment pathway because of its tumor suppressor
properties in paclitaxel-sensitive breast cancer. In breast cancer, FoxO3a has been shown
to upregulate the pro-apoptotic protein, BIM, which was effective at inducing apoptosis.
In certain types of breast cancer treated with the chemotherapy drug paclitaxel it
appeared FoxO3a was upregulated, subsequently increasing BIM expression and
decreasing cell survival (Arden, 2006). Studies with over-expression of FoxO3a have
supported the tumor suppressive capabilities as well. In in vitro studies, over-expression
of FoxO has shown inhibition of tumor growth (Zhang, et al., 2011). Breast cancer in
vivo studies revealed that based on tumor size and the localization of FoxO3a into the
cytoplasm indicated a correlation to poor survival (Zhang, et al., 2011). Cytoplasmic
FoxO3a is associated with poor survival in breast cancer, and Akt has been shown to be
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positively correlated with worse outcomes in patients, including distance metastasis in
endocrine treated breast cancer (Tokunaga, et al., 2006). FoxO3a and another tumor
suppressor p53 may coordinate to signal tumor suppression. There is data demonstrating
that both p53 and FoxO3a function together to mediate the effects of cellular stress, and
by overlapping modes of target gene regulation, both can suppress tumorigenesis (Zhang,
et al., 2011). This relationship between the two tumor suppressors may explain why over
half of cancers develop because of a mutation in p53. PTEN is another tumor suppressor
that is commonly mutated in cancer with FoxO3a. In healthy tissue, FoxO3a targets
PTEN and enhances transcription of PTEN to positively reinforce the function of tumor
suppression (Zhang, et al., 2011). When mutated in cancer, PTEN loses it’s function
allowing for hyperactivated PI3K/Akt to take over and drive tumor survival (Zhang, et
al., 2011). The tumor suppressive properties of Foxo3a could potentially be beneficial in
developing new therapeutics, most of which could ultimately induce apoptosis of tumor
cells and improve survival in cancer patients.
FoxO3a may not always act as a tumor suppressor as there is new evidence to
suggest it may even play a role in tumor promotion. It has been noted that about 70% of
invasive ductal breast carcinomas have nucleated FoxO3a while benign tumors express
90% cytosolic FoxO3a meaning active FoxO3a may promote invasion among other
tumor promoting features (Storz, et al., 2009). A study by Jin et al., in 2004 observed
activated FoxO3a in clinical breast cancer was associated with lymph node metastasis
and poor prognosis (Zhang, et al., 2011). Storz et al. conducted an investigation on how
FoxO3a promotes tumor invasion through the induction of MMPs. MMPs are critical
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mediators of ECM degradation in tumor progression and have been indicators of poor
prognosis in colorectal cancer. It’s possible that FoxO3a could regulate the expression of
MMPs to promote tumor expansion. In order to determine the role of FoxO3a during
tumor expansion, the researchers injected MDA-MB-231 cells both normal and depleted
of FoxO3a in nude mice. They observed that the knockdown of FoxO3a in MDA-MB231 cells did not have a significant effect on the proliferation rate and apoptosis, but the
tumors were small in volume and weight. Storz and colleagues investigated FoxO3a and
MMPs, specifically MMP-9 and MMP-13 both of which are detected in tumor cells and
tissue, but low in healthy tissue. They found active FoxO3a significantly enhanced the
MMP-9 and MMP-13 expression. As solid tumors grew they began to lose serum factors
and the restrictions in the cell induced FoxO3a to mediate MMP expression and an
increased invasion potential of the tumor cells. Overall their data pointed to the fact that
active FoxO3a could have a role in promoting tumor expansion and metastasis by
regulating MMP-9 and MMP-13 expression instead of promoting apoptosis (Storz, et al.,
2009).
A few publications support the pro-oncogenic function of FoxO3a, the most
recent of which, by Marlow et al., was published in 2012. This group looked at FoxO3a
driving proliferation in anaplastic thyroid carcinoma calling the change in FoxO3a
function a paradigm shift. In anaplastic thyroid carcinoma (ATC), they hypothesized that
by silencing Akt through shRNA or inhibitors would lead to high nuclear FoxO3a and
therefore increasing antitumor activity. They found that the high nuclear activity of
FoxO3a transcriptionally upregulated the cyclin A1 gene expression, leading to enhanced
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cell cycle progression and proliferation (Marlow, et al., 2012). ATC is a highly invasive
and aggressive form of cancer indicating the shift in the role of FoxO3a could occur in
other aggressive cancers including TNBC. Marlow et al were able to demonstrate that
over-expression of Akt is not entirely sufficient to inactivate FoxO3a by studying
immunohistochemistry (ICC) expression of FoxO3a in several ATC cell lines. They
exposed several ATC to exogenous AKT and found minimal difference in the amount of
FoxO3a relocalized in the cells before and after exposure. This data could indicate a
trend to the FoxO3a shuttling mechanism using pathways other than Akt. It is speculated
that there is a shift in the role of FoxO3a during tumor progression from benign to
metastatic, but the mechanism for this is yet to be discovered (Marlow, et al., 2012).
Along with the two studies previously discussed there are a few that indicate
nuclear FoxO3a in some forms of breast cancers is associated with lymph node
metastasis and overall poor survival (Chen, et al., 2010). This information could change
the role of FoxO3a as a therapeutic target for highly aggressive cancers. Therapeutics
that activate FoxO3a in early forms or less invasive cancers could be beneficial, but this
new information about highly invasive or later stage cancers could cause the FoxO3a
therapeutics may promote tumor growth and metastasis. Nuclear FoxO3a in invasive
cancers, such as TNBC could be a potential new prognostic marker.
3D Cell Culture
All of the information previously discussed would not exist if there weren’t a
reliable cell culture model to study the many aspects of cancer growth and development.
In vivo studies in mice or other living organisms are ideal for representatives of the
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human body in cancer research, but in vitro studies are essential when understanding the
mechanisms involved in cancer progression. There are advantages to in vitro studies
including cost effective, a more detailed analysis about what is occurring in the cells and
consistency that can be difficult to replicate in living organisms.
Traditionally, cell culture was conducted in what is referred to as monolayer or
2D where cells are grown directly on a plastic or glass surface, but researchers found that
this method was not always beneficial. Some advantages to 2D cell culture methods
include convenience and being inexpensive compared to other methods (Kim, 2005).
Cell culture using 2D allows for excessive cell growth that is similar to malignancy
(Weaver, et al., 1995). In cancer research, however, it is problematic to study the
physiology and tumorigenesis of the cancer cells in 2D cell culture (Kim, 2005). Other
disadvantages to 2D culture especially in breast cancer research, include poor adherence
and growth in an artificial environment, the cells lack structural architecture limiting
transport studies, and there is poor viability with organ cultures (Kim, 2005). One of the
biggest disadvantages in using 2D culture in breast cancer is the lack of stroma (Kim,
2005), which is made up of cells, connective tissue, blood and lymph vessels, fibroblasts
and inflammatory cells (Weaver, et al., 1995). The stroma makes up about 80% of
resting breast volume (Weaver, et al., 1995). The 2D cell culture does not mimic the
glandular environment of the breast so investigating cellular events including
proliferation, apoptosis, polarity of the cells, and differentiation for both normal and
tumorigenic breast epithelial cells does not provide an accurate depiction (Debnath,
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Muthuswamy, & Brugge, 2003). This data leads to the need to develop a 3D cell culture
model to mimic the breast tumor environment.
The stromal-epithelial interactions help to regulate mammary epithelial cell
growth and differentiation and adapt to changes in development (Kass, et al., 2007).
During a woman’s life the breast is a tissue that goes through various changes, sometimes
in short periods of time. Breast tissue changes during its initial development during
puberty, menstrual cycles, pregnancy to prepare for milk production, lactation,
remodeling after lactation, and menopause (Kass, et al., 2007). Interactions between the
stroma components and epithelial cells as well as the ECM are important in
tumorigenesis (Weaver, et al., 1995). Tumor cells and stroma communicate with each
other throughout growth and differentiation (Dvorak, et al., 2011), and tumor cells must
interact with the stroma during metastasis in order to reach the blood stream and at the
secondary site to develop secondary tumors. Most tumors require stroma but the amount
of stroma does not dictate the malignancy of the cancer (Dvorak, et al., 2011).
3D cell culture allows for many advantages over 2D culture and in some cases
even in vivo studies. The 3D cell culture method allows researchers to look at multiple
cells with different phenotypes at one time, which is similar to that of a traditional tumor
environment (Kim, 2005). The 3D cell culture mimics avascular conditions, which is
often the case in real tumor development before angiogenesis occurs (Kim, 2005). 3D
allows for a better resemblance of cell shape, cell adherence, migration, interaction
between epithelial and stromal cell, and other cell-cell interactions (Kim, 2005). Cells in
3D culture often demonstrate similar responses to therapies in vivo for example, MDA-
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MB-231 cells in 2D culture showed a much lower sensitivities to certain drugs compared
to in vivo and 3D culture (Kim, 2005).
There are many different types of 3D cell culture methods that are in use and each
has specific advantages to different areas of interests and different cell types. Each has
its own disadvantages as well, but these vary based on the mechanism being studied.
These techniques are constantly developing and improving the various 3D techniques.
One particular technique is liquid overlay culture, more specifically a reconstituted
membrane referred to as Matrigel. This is likely one of the more common and consistent
techniques for growing cells with adhesion forces between cells (Debnath, Muthuswamy,
& Brugge, 2003). In a 2003 article by Debnath, Muthuswamy and Brugge used the liquid
overlay technique with Matrigel to study morphogenesis and oncogensis of mammary
epithelial cells. Debnath and colleagues used the MCF-10A cell line, an immortalized
normal mammary epithelial cell lines. MCF-10A when passaged for a long length of
time can begin to form fibroblastic or spindle-shaped cells characteristic of cancer cells.
Debnath et al were interested in using 3D cell culture to determine if the MCF-10A cells
would form acinar structures with low proliferation, normally seen in actual mammary
tissue. In 2D cultures the cells fail to form acini, but did in vivo, which was why a 3D
culture technique needed investigation. The results they obtained concluded, that when
plated on Matrigel, the MCF-10A cells formed acini with a hollow lumen and a low
proliferation. The lumen was a very important result because it exhibited cells that did
not come in contact with the basement membrane, underwent anoikis. This discovery
mimics normal cell behavior, previously discussed in the EMT section comparing normal
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and malignant cells and the importance of the attachment to the ECM and E-cadherin.
The methods from this article have allowed for further research to be conducted and
provide insight into understanding mechanisms that could be involved in tumor
progression of breast cancer (Debnath, Muthuswamy, & Brugge, 2003). This article was
crucial in the research conducted for this study with the highly invasive TNBC cell lines
BT-549, MDA-MB-157 and MDA-MB-231. This study was able to follow the same 3D
culture protocol from this article to compare the effects of culture environments on the
expression of CD44, Ki67, and FoxO3a.
Summary
Triple negative breast cancer is a highly invasive cancer that does not behave like
other forms of breast cancer. The ability to evade traditional treatments has led
researchers to investigate other targets such as the cellular processes of EMT and MET.
Using the known prognostic markers CD44+ and Ki67 could help to further understand
the mechanism when cancer cells are undergoing EMT and MET. FoxO3a may play a
role in these cellular processes. Whether FoxO3a is a tumor suppressor or tumor
promoter in TNBC this could serve as a prognostic tool and a possible therapeutic target.
Furthermore, the use of 3D cell culture techniques could have an impact on better
understanding these mechanisms in not only TNBC but other cancers as well.
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CHAPTER THREE
MATERIALS AND METHODS

Cell Culture, Cell Resuspension, and Matrigel Handling
Human triple negative breast cancer cell lines BT-549, MDA-MB-157, and
MDA-MB-231 were purchased from ATCC (Manasses, VA, USA). BT-549 cells were
maintained in ATCC RPMI 1640 media (ATCC #302001) supplemented with 10% fetal
bovine serum (Atlanta Biologicals #S12450) and 0.023 IU/mL bovine insulin (Sigma
#I0516) and incubated in a Forma Scientific 3130 CO2 water jacketed incubator at 37°C
with 5% CO2. MDA-MB-157 cells were maintained in ATCC L-15 media (ATCC
#302008) supplemented with 10% fetal bovine serum and incubated in a Napco 6500
CO2 water jacketed incubator at 37°C with 0% CO2. MDA-MB-231 cells were
maintained in Hyclone DMEM/high glucose media (Thermo #SH300222) supplemented
with 10% fetal bovine serum, 1% Penicillin-Streptomycin solution (Cellgro #30-002-CI),
and 1% sodium pyruvate (Cellgro #25-000-CI) and incubated in a Forma Scientific 3130
CO2 water jacketed incubator at 37°C with 5% CO2. All cell lines were grown in 250 mL
polystyrene BD Falcon™ culture flasks (#353136). All cell culture methods were
performed in a biological safety class II type A hood.
The three cell lines were allowed to grow in culture flasks until they reached
between 50% and 95% confluency before being resuspended and counted for use in the
assays. The respective media was removed from the culture flasks and approximately 7
mL of Corning Cellgro™ Cellstripper® (#25-056-CI) was added to the flask and
incubated at 37°C with 5% CO2 for 5 minutes. Cellstripper® was pipetted up and down
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to wash the flask in order to remove adhered cells from the walls of the flask. The
Cellstripper® solution containing detached cells was removed from the flask and added
to a 15 mL VWR sterile centrifuge tube (#89039-664). The resuspended cells were
centrifuged at 125 g with a JS-7.5 rotor for 5 minutes at 23°C in a Beckman J2-21M/E
centrifuge. The supernatant was discarded and phosphate buffered saline (PBS) (Sigma
#P4417100TAB) was added to wash and resuspend the cell pellet. The cells were
centrifuged again following the same settings as the initial centrifuge protocol. The PBS
supernatant was discarded and the cell pellet was resuspended with 1 mL of the
respective media depending on the cell line. The cells were counted using a solution of
trypan blue solution (Cellgro #25-900-CI) with 10% of the resuspended cell solution.
The Trypan blue solution containing resuspended cells was pipetted onto a Bright-Line
Hemacytometer with two counting platforms. The cell concentration was calculated
using the equation of cells needed divided by the amount of cells counted. The plating
amount of cells was dependent on the assay being performed.
Growth Factor Reduced Matrigel from BD Biosciences (#3567231 San Jose, CA,
USA) was obtained and thawed on ice for a several hours in order for the gel to become a
liquid. Matrigel remains liquid on ice but solidifies at room temperature, therefore it was
kept on ice at all times. Matrigel was added in 1 mL aliquots to labeled 1.5 mL
microcentrifuge tubes and stored at -20°C until needed for assays.
2D and 3D Culture Assays
2D Assays
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Cells were plated at a density of 5.6 x 104 cells in each well of the Lab-Tek® 4
well Permanox® Chamber Slides™ (# 177437) in a final volume of 400 µL of the
appropriate media for the cell line being used. Slides containing BT-549 and MDA-MB231 cells were incubated at 37°C with 5% CO2 overnight to allow cell adhesion before
assays were performed. Slides containing MDA-MB-157 cells were incubated at 37°C
with 0% CO2 for 36 hours before assays were performed. Following incubation for cell
adherence the slides were immunofluorescent stained and imaged for analysis.
3D Assays
Aliquots of Matrigel were thawed on ice for about 3 hours. Beveled graduated 1200 µL pipet tips and 4 well Chamber Slide were also stored on ice to prevent premature
solidifying of the Matrigel. A volume of 95 µL of Matrigel was pipetted into each well
of the 4 well chamber slides and spread to cover the surface of the wells with the 1-200
µL pipet tips being careful to not produce bubbles in the Matrigel. The slides were
incubated at 37°C with 5% CO2 for 20 minutes to allow for Matrigel to fully solidify.
Cells were plated at a density of 5.6 x 104 cells in each well of the 4 well chamber slides
in a final volume 800 µL of the appropriate media containing 2% Matrigel. The slides
containing BT-549 and MDA-MB-231 cells were incubated at 37°C with 5% CO2 for 36
hours to allow cell adhesion before the assays were performed. The slides containing
MDA-MB-157 cells were incubated at 37°C with 0% CO2 for 36 hours before the assays
were performed. Following incubation for cell adherence, the slides were
immunofluorescent stained and imaged for analysis.
siRNA and Western Blot
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FOXO3 Silencer® Select Pre-designed siRNA (#4392420) and Lipofectamine®
RNAiMAX reagent (#13778-075) were purchased from Invitrogen (Grand Island, NY,
USA). A stock solution of 5 µM of siRNA using the FoxO3a siRNA and water provided
in the Silencer® Select siRNA kit from Invitrogen was stored at -20°C in between assays.
A western blot was performed to confirm FoxO3a expression was knocked down in
MDA-MB-231 cells.
Western Blot
MDA-MB-231 cells were plated at a density of 2.9 x 105 cells in a final volume of
2.9 mL supplemented DMEM/high glucose media in two 3.5 mm x 10 mm cell culture
dishes. The plated cells were incubated at 37°C with 5% CO2 overnight to allow for cell
adhesion. The following day the media was discarded and replaced with serum and penstrep free media. The cells were incubated at 37°C with 5% CO2 overnight. A 0.1 µM
siRNA solution was prepared from the 5 µM stock solution in 250 µL of DMEM/high
glucose media. The lipofectamine solution was prepared by mixing 6 µL of the
lipofectamine in 250 µL of DMEM/high glucose media. The 0.1 µM siRNA solution and
lipofectamine solutions were combined and incubated at room temperature for 20
minutes before addition to the cells. The entire volume of the combined
siRNA/lipofectamine solution was added to one of the culture dishes while the other dish
served as a control receiving 500 µL of the DMEM/high glucose media. The dishes were
incubated for 48 hours at 37°C with 5% CO2. Cells were lysed in order to detect proteins
in western blot. The lysis solution consisted of 50 µL of a 10X lysis solution in 445 µL
and 5 µL of 100mM phenylmethanesulfonyl fluoride (PMSF) solution (Fluka Analytical
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#93482). The media was discarded from the cell culture dishes and the cells were
incubated with 100 µL each of the lysis solution for 5 minutes on ice. The cell culture
dishes were vigorously scraped to remove the lysed cells adhered to the bottom of the
dishes. The lysed cell solution from the culture dishes was pipetted into labeled 1.5 mL
microcentrifuge tubes. Lysed cell solutions were centrifuged at 14,000 g for 10 minutes
in a microcentrifuge to remove the non-protein cell components and the supernatant was
collected. A Mini-Protean TGX Gel and kD from BioRad (#456-1094, Hercules, CA,
USA) was placed in the BioRad electrophoresis apparatus for electrophoresis of the
samples. The electrophoresis apparatus was filled with 700 mL of 1X running buffer
before the samples were added to the gel. The cell samples were prepared by adding 15
µL of each of the sample each to a solution of 15 mL of BioRad Laemmli Sample Buffer
(#161-0737) containing 5% 2-mercaptoethanol and vortexed briefly to thoroughly mix
the samples. A volume of 8 µL of Precision Plus Protein Kaleidoscope Standard from
BioRad (#161-0375) was standard. The gel was electrophoresed at 200 V until the
standards and samples reached the bottom of the gel. Following electrophoresis the gel
was washed with transfer buffer. The gel was transferred to a BioRad PVDF Immunoblot Membrane (162-0175) for protein blotting in a BioRad transfer apparatus with
transfer buffer at 100 V for 60 minutes. Following transfer, the membrane was blocked
in a blotto solution consisting of 5% Carnation® Instant Nonfat Dry Milk in nanopure
water for 1 hour at room temperature on a shaker at low to medium speed. The
membrane was washed three times with Tris-Buffered Saline (TBS) solution before the
primary antibodies were added. The primary antibodies, FoxO3a rabbit monoclonal
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(#3280-1) from Epitomics® (Burlingame, CA, USA) and β-actin (13E5) rabbit
monoclonal (# 4970) from Cell Signaling Technology® (Danvers, MA, USA) were used.
Both of the primary antibodies were incubated together with the membrane each at a
1:1000 dilution in TBS for 1 hour at room temperature on a shaker at low to medium
speed. The primary antibodies were removed and the membrane was washed three times
with TBS before the secondary antibodies were added. The secondary antibody, antirabbit IgG, HRP-linked (#7074) from Cell Signaling Technology® (Danvers, MA, USA)
was added to the membrane at a 1:1000 dilution in TBS for 1 hour at room temperature
on a shaker at low to medium speed. The membrane was washed three times with TBS.
The proteins on the membrane were detected using the Peroxidase Substrate Kit Vector®
VIP (#SK-4600) Vector Laboratories, Inc. (Burlingame, CA, USA) mixed in PBS and
incubated with the membrane for 20-30 minutes or until the protein bands were
completely visible. The membrane was briefly washed with water and left to dry at room
temperature overnight before analysis.
2D Assays
MDA-MB-231 cells were plated at a density of 5.6 x 104 cells in a final volume of
400 µL of DMEM/high glucose supplemented media in each well of the 4 well chamber
slides. The cells were incubated at 37°C with 5% CO2 overnight. The media was
discarded and replaced with serum and pen-strep free DMEM/high glucose media and
incubated again at 37°C with 5% CO2 overnight. A 0.1 µM siRNA solution was made
from the 5 µM stock solution in 49 µL of DMEM/high glucose media for each well of the
chamber slide. A lipofectamine solution was made by mixing 1 µL of the lipofectamine
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in 49 µL of DMEM/high glucose media for each well of the chamber slide. The 0.1 µM
siRNA solution and lipofectamine solutions were combined and incubated at room
temperature for 20 minutes before addition to the cells. The entire volume of the
combined siRNA/lipofectamine solution was added to each well of the chamber slide and
incubated for 48 hours at 37°C with 5% CO2. The slides were stained with
immunofluorescence and imaged for analysis.
3D Assays
Aliquots of Matrigel were thawed on ice for about 3 hours. Beveled, graduated 1200 µL pipet tips and 4 well chamber slide were also stored on ice to prevent premature
solidifying of the Matrigel. A volume of 95 µL of Matrigel was pipetted into each well
of the 4 well chamber slides and spread to cover the surface of the wells with the 1-200
µL pipet tips, being careful to not produce bubbles in the Matrigel. The slides were
incubated at 37°C with 5% CO2 for 20 minutes to allow for Matrigel to fully solidify.
MDA-MB-231 cells were plated at a density of 5.6 x 104 cells in each well of the 4 well
chamber slides in a final volume of 800 µL of the supplemented DMEM/high glucose
media containing 2% Matrigel. The cells were incubated at 37°C with 5% CO2 for about
36 hours. The media was discarded and replaced with serum and pen-strep free
DMEM/high glucose media and incubated at 37°C with 5% CO2 overnight. The 0.1 µM
siRNA solution was made from the 5 µM stock solution in 49 µL of DMEM/high glucose
media for each well of the chamber slides. The lipofectamine solution was made with 1
µL of the lipofectamine in 49 µL of DMEM/high glucose media for each well of the
chamber slides. The 0.1 µM siRNA solution and lipofectamine solutions were combined
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and incubated at room temperature for 20 minutes before being added to the cells. The
entire volume of the combined siRNA/lipofectamine solution was added to each well of
the chamber slide and was incubated for 48 hours at 37°C with 5% CO2. The slides were
stained with immunofluorescence and imaged for analysis.
Wound Healing Assay
MDA-MB-231 cells were plated at a density of 5.6 x 104 cells in a final volume of
400 µL of DMEM/high glucose supplemented media in each well of the 4 well chamber
slides. The cells were incubated at 37°C with 5% CO2 overnight. Using a 1-200 µL
beveled graduated tips, approximately 1 mm cell free area was scraped across each well
and the slides were incubated for 0, 1, 24, 48, and 72 hours at 37°C with 5% CO2 before
being immunofluorescence stained and imaged for analysis.
Immunofluorescence
Untreated, siRNA Treated and Wound Healing Assay
Following the incubations the media was discarded and the cells were washed
briefly with sterile PBS. The cells were fixed to the slides with 4% paraformaldehyde
(USB Corporation #19943) and incubated for 15 minutes at room temperature. The 4%
paraformaldehyde was discarded and the cells were washed briefly with sterile PBS.
Cells were permabilized with 0.5% v/v Triton X (Sigma #T-6878) in PBS for 15 minutes
at room temperature. The triton X solution was discarded and the cells were washed
three times in PBS. The cells were blocked with 10% goat serum blocking solution and
incubated for 1 hour at room temperature. The blocking solution was discarded and 200
µL of primary antibodies was added to the wells. One slide received the primary
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antibodies anti-CD44 rat monoclonal (#217594) from Calbiochem® (Darmstadt,
Germany) at a 1:200 dilution and anti-FOXO3a, clone EP1949Y rabbit monoclonal
(#041007) from Millipore ™ (Billerica, MA, USA) at a 1:50 both in 10% goat serum
blocking solution. A second slide received the primary antibodies mouse anti-human Ki67 antibody (#550609) from BD Pharmingen™ (San Jose, CA, USA) at a 1:50 dilution
and anti-FOXO3a at a 1:50 both in 10% goat serum blocking solution. The primary
antibodies were added to only 3 of the 4 wells on the untreated and siRNA treated slides.
The 4th well was the control and received 200 µL of 10% goat serum blocking solution.
In the wound healing assay, each slide contained one well with CD44+ and FOXO3a
primary antibodies and a second well with Ki67 and FOXO3a primary antibodies. Two
wells were controls receiving only 10% goat serum blocking solution. The slides were
incubated for 1 hour in a humid box at room temperature. The primary antibodies were
removed and the cells were washed with 10% goat serum blocking solution three times.
Secondary antibodies in a total volume of 200 µL were added to each well of the chamber
slides. The slide incubated with the CD44+ and FOXO3a primary antibodies received the
secondary antibodies Alexa Fluor® 488 goat anti-rat IgG (H+L) (#A11006) from Life
Technologies™ (Carlsbad, CA, USA) and Alexa Fluor® 594 goat anti-rabbit IgG (H+L)
(#A11037) from Life Technologies™ (Carlsbad, CA, USA) both at a dilution of 1:400 in
10% goat serum blocking solution. The second slide incubated with the Ki67 and
FOXO3a primary antibodies received the secondary antibodies Alexa Fluor® 488 goat
anti-mouse IgG (H+L) (#A11029) from Life Technologies™ (Carlsbad, CA, USA) and
Alexa Fluor® 594 goat anti-rabbit IgG (H+L) both at a dilution of 1:400 in 10% goat
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serum blocking solution. The slides were incubated with the designated secondary
antibodies for 1 hour in a humid box at room temperature. The secondary antibodies
were removed and the wells were washed three in PBS. The cells were incubated with
the nuclear stain DAPI at a 1:2000 dilution in PBS for 15 minutes in a humid box at room
temperature. DAPI was discarded and the plastic wells and gel separator on the chamber
slides were removed. Each slide was washed briefly with PBS and a micro cover glass
24 X 50 mm No.1.5 was placed on the slides. The slides were imaged for further
analysis.
Imaging and Image Analysis
Imaging
Images were collected using a CRI Nuance Multispectral Imaging System
(Lincolnshire, UK). Nine images per slide plus one control image were photographed for
all the untreated and siRNA slides. The analyzed images for untreated and siRNA slides
were collected at 20x magnification with a 10x magnification eyepiece. Four images plus
one control image were collected for the wound healing assays. All of the analyzed
images for wound healing assays used a 5x magnification with 10x magnification
eyepiece.
CellProfiler
The CellProfiler cell image analysis software from the Broad Institute
(Cambridge, MA, USA) was used to analyze the images obtained with the CRI imaging
system. A CellProfiler pipeline was constructed for the CD44+ and FOXO3a images, and
a separate pipeline was constructed for the Ki67 and FOXO3a images. Each pipeline

34

measured the fluorescence intensities of the labeled antibodies and DAPI as primary
objects. The data output was saved in Microsoft Excel for statistical analysis.
ImageJ
ImageJ was obtained from the Research Services Branch of the National Institute
of Health website. Images from the wound healing assay were opened in ImageJ. Each
image was analyzed to determine the percentage of the wound area covered by cells for
each incubation time period. The data output was saved in Microsoft Excel for statistical
analysis.
Proliferation Assay
A CellTiter 96® AQueous Non-Radioactive Cell Proliferation 1000 Assays kit
(#G5421) was purchased from Promega (Madison, WI, USA). The 20 mL of MTS
solution and the 1 mL PMS solution included in the kit were mixed together. Aliquots of
1 mL were pipetted into 1.5mL microcentrifuge tubes and stored in a dark box to reduce
the amount of light exposure at -20°C until needed for the assays. A MICROTEST™
Tissue Culture 96 well, flat bottom with low evaporation lid plate (#353072) from Becton
Dickinson Labware was used for proliferation assays.
2D Proliferation Assay
MDA-MB-231 cells were plated at a density of 1 x 104 cells in a final volume of
100 µL of supplemented DMEM/high glucose media in triplicate in a 96 well plates. The
cells were incubated for either 0, 1, 2, 4, 6, 8, 24, 48, or 72 hours at 37°C with 5% CO2.
A 1 mL aliquot of MTS/PMS solution for the assay was thawed and wrapped in
aluminum foil to reduce light exposure. A 20 µL volume of the thawed MTS/PMS
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solution under low light conditions was added to each well containing cells, and the
control wells contained media. The plate was incubated for 2 hours at 37°C with 5% CO2
and analyzed with PowerWaveX microplate reader and KC4 program. The data output
was saved in Microsoft Excel for statistical analysis.
3D Proliferation Assay
Aliquots of Matrigel were thawed on ice for 3 hours. Beveled graduated 1-200
µL pipet tips and 4 well Chamber Slide were stored on ice to prevent premature
solidifying of the Matrigel. A volume of 25 µL of Matrigel was pipetted into each well
of the 96 well plate needed for the assay and spread out to cover the surface of the wells
with the 1-200 µL pipet tip being careful to not produce bubbles in the Matrigel. The
plate was incubated at 37°C with 5% CO2 for 20 minutes to allow for Matrigel to fully
solidify. MDA-MB-231 cells were plated at a density of 1 x 104 cells in a final volume
of 100 µL of supplemented DMEM/high glucose media in triplicate in a 96 well plates.
The cells were incubated for 0, 1, 2, 4, 6, 8, 24, 48, or 72 hours at 37°C with 5% CO2. A
1 mL aliquot of MTS/PMS solution for the assay was thawed and wrapped in aluminum
foil to reduce light exposure. A 20 µL volume of the thawed MTS/PMS solution under
low light conditions was added to each well containing cells and control wells contained
media. The plate was incubated for 2 hours at 37°C with 5% CO2. The plate was read
using a PowerWaveX microplate reader and KC4 program. The data output was saved in
Microsoft Excel for statistical analysis.
Statistical Analysis

36

CellProfiler data for each of the three untreated cell lines were analyzed based on
a two factor treatment structure, with factor 1 being the 2D and 3D cell culture
environments, and factor 2 being the two staining regimens. The experiment structure
was a randomized complete block split plot with the slides as the blocks and the images
as the split plot. ANOVA was used to test for the main effect of the 2D and 3D
environments, the main effect of staining regimen, and the interaction effect of
environment and staining. When significant effects were found; then Fisher’s protected
least significant difference test was used to compare means.
CellProfiler data for the siRNA treated and untreated MDA-MB-231 cell line in
2D and 3D environments were analyzed based on a three factor treatment structure, with
factor 1 being siRNA supplementation, factor 2 being the 2D and 3D cell culture
environments, and factor 3 being the two staining regimens. The experiment structure
was a randomized complete block split plot with the slides as the blocks and the images
as the split plot. ANOVA was used to test for the main effect of the 2D and 3D
environments, the main effect of staining regimen, the main effect of siRNA
supplementation, and the interaction effects of environment, staining, and
supplementation. When significant effects were found; then Fisher’s protected least
significant difference test was used to compare means.
Proliferation assay data for the MDA-MB-231 were analyzed based on a twofactor treatment structure, with factor 1 being the 2D and 3D cell culture environments,
and factor 2 being the incubation times. The experiment structure was completely
randomized. ANOVA was used to test for the main effect of the 2D and 3D
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environments, the main effect of incubation times, and the interaction effect of
environment and incubation times. When significant effects were found; then Fisher’s
protected least significant difference test was used to compare means.
Wound healing assay data for the MDA-MB-231 cell line were analyzed based on
a 1-factor treatment structure with the incubation times being the one factor. The
experiment structure was completely randomized. ANOVA was used to test for the
effect of the incubation time. When significant effects were found; then the Fdistribution of the null hypothesis was used to compare means.
All results were analyzed using JMP 10.0.0 software from SAS Institute (Cary,
NC, USA). All statistical tests were performed with α = 0.050.
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CHAPTER FOUR
RESULTS

Environment vs. Protein Expression in Three Cell Lines
BT-549 Cell Line
Figure 1 is a representation of the images that were used for analysis of the BT549 cells stained for either CD44+ and FoxO3a or Ki67 and FoxO3a. CD44+ was stained
green in the top two images while Ki67 was stained green in the bottom two images.
FoxO3a was stained red in the images and the nuclei were stained blue with DAPI. The
cells in the 3D images appeared to grow closer together than the cells grown in 2D. The
image of cells grown in 3D and stained for Ki67 and FoxO3a appeared to have more
FoxO3a and most of it appeared to be in the cytoplasm than that of the Ki67 and FoxO3a
cells in the 2D culture environment. The images of the cells stained for CD44+ and
FoxO3a in both 2D and 3D culture environments did not appear to show a difference in
the amount or location of FoxO3a.
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The effect of cell culture environment on the expression of CD44+, Ki67, and
FoxO3a was investigated in the triple negative breast cancer cell line BT-549.
Cells stained for CD44+ and FoxO3a in both 2D and 3D culture environments
showed a difference between the mean intensity of CD44+ and the mean intensity of
FoxO3a. There was no significant difference in the mean intensity of FoxO3a between
cells grown in either 2D or 3D culture environment, nor was there a significant difference
in the mean intensity of CD44+ between the cells grown in either 2D or 3D culture
environment.
Cells stained for Ki67 and FoxO3a in 2D did not show a significant difference in
the mean intensities between Ki67 and FoxO3a, but a significant difference between the
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mean intensity of Ki67 and the mean intensity of FoxO3a in 3D culture environment was
observed. The FoxO3a mean intensities showed a significant difference between 2D and
3D culture environment, but there was not a significant difference in the mean intensity
of Ki67 in cells grown in either 2D and 3D culture environments (Figure 3).
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MDA-MB-157 Cell Line
Figure 4 is a representation of the images that were used for analysis of the MDAMB-157 cells stained for either CD44+ and FoxO3a or Ki67 and FoxO3a. CD44+ was
stained green in the top two images while Ki67 was stained green in the bottom two
images. FoxO3a was stained red in the images and the nuclei were stained blue with
DAPI. The cells in the 3D images appeared to grow closer together than the cells grown
in 2D. The morphology of the cells in the image for those stained for CD44+ and FoxO3a
grown in the 3D culture environment appeared to be slightly different than that of the
cells in the 2D culture environment. In both of the 3D images there appeared to be more
FoxO3a staining, predominantly found in the nuclei of the cells.
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The effect of cell culture environment on the expression of CD44+, Ki67, and
FoxO3a was investigated in the triple negative breast cancer cell line MDA-MB-157.
Cells stained for CD44+ and FoxO3a showed a significant difference between the
mean intensity of CD44+ and the mean intensity of FoxO3a in both the 2D and 3D cell
culture environments. There was a significant difference in the mean intensities of
FoxO3a between the 2D and 3D cell culture environments but there was no significant
difference observed in the mean intensities of CD44+ between the 2D and 3D cell culture
environments (Figure 5).
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Cells stained for Ki67 and FoxO3a in the 2D culture environment did not show a
significant difference between the mean intensity of Ki67 and the mean intensity of
FoxO3a, but a significant difference was observed between the mean intensity Ki67 and
the mean intensity of FoxO3a in the 3D culture environment. The mean intensities of
FoxO3a showed a significant difference between the 2D and 3D cell culture environment.
There was not a significant difference in the mean intensities of Ki67 between the 2D and
3D cell culture environments (Figure 6).
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MDA-MB-231 Cell Line
Figure 7 is a representation of the images that were used for analysis of the MDAMB-231 cells stained for either CD44+ and FoxO3a or Ki67 and FoxO3a. CD44+ was
stained green in the top two images while Ki67 was stained green in the bottom two
images. FoxO3a was stained in the images and the nuclei were stained blue with DAPI.
In both of the 3D cell culture images there appeared to be an increase in the amount of
FoxO3a being stained. It appeared that the 3D images show more FoxO3a located in the
cytoplasm than in the 2D images.
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The effect of cell culture environment on the expression of CD44+, Ki67, and
FoxO3a was investigated in the triple negative breast cancer cell line MDA-MB-231.
Cells stained for CD44+ and FoxO3a did not show a significant difference
between the mean intensity of CD44+ and the mean intensity of FoxO3a in either 2D or
3D culture environment. Environment did not have a significant effect on the mean
intensities of FoxO3a between the 2D and 3D cell culture. The same was observed in the
mean intensities of CD44+ between the 2D and 3D cell culture environments (Figure 8).
Cells stained for Ki67 and FoxO3a did not show a significant difference between
the mean intensity of Ki67 and the mean intensity of FoxO3a in either 2D or 3D culture
environment. A significant difference in the mean intensities of FoxO3a was seen
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between the 2D and 3D cell culture environments, but a significant difference was not
observed in the mean intensities of Ki67 between the 2D and 3D cell culture environment
(Figure 9).

47

siRNA Western Blot
A western blot was performed to determine if the pre-designed FoxO3a siRNA
could knockdown expression of FoxO3a in MDA-MB-231 cells with β-actin as a control
to demonstrate there was no change in the amount of protein in each sample. FoxO3a
was detected in both the control and siRNA treated cells around its molecular weight of
90 kD. β-actin was detected in both the control and siRNA treated cells around its
molecular weight of 45 kD. Figure 10 shows that there was a knockdown of FoxO3a, but
it was not a complete knockdown. A significant change in expression of β-actin was not
observed in either the control or in the siRNA treated cells.
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Environment Effects and Protein Expression in siRNA Treated and Untreated
MDA-MB-231 cells
Figure 11 and figure 12 are representations of the images that were used for
analysis of the MDA-MB-231 cells untreated and treated with the pre-designed FoxO3a
siRNA. CD44+ was stained green in the images in figure 11 while Ki67 was stained
green in the images in figure 12. FoxO3a was stained red in the images and the nuclei
were stained blue with DAPI. Figure 11 represents cells stained for CD44+ and FoxO3a
and depicts images of the untreated MDA-MB-231 cells that were discussed in the
previous section and MDA-MB-231 cells treated with siRNA in both the 2D and 3D cell
culture environments. In both the 2D and 3D cell culture environments it appeared that
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the untreated MDA-MB-231 cells were expressing more FoxO3a than the treated cells.
From the siRNA treated cell images there did not appear to be a significant difference in
the location and expression of FoxO3a. Figure 12 represents cells stained for Ki67 and
FoxO3a and depicts images of the untreated MDA-MB-231 cells that were discussed in
the previous section and MDA-MB-231 cells treated with siRNA in both the 2D and 3D
cell culture environments. In both the 2D and 3D cell culture environments it appeared
the untreated MDA-MB-231 cells were expressing more FoxO3a than the treated cells.
There appeared to be a slightly higher expression of FoxO3a in the siRNA treated cells
grown in the 3D cell culture environment than in the siRNA treated cells grown in the 2D
cell culture environment.
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Environment
The effects of environment on the expression of CD44+, Ki67 and FoxO3a in predesigned FoxO3a siRNA treated MDA-MB-231 cells or that of untreated MDA-MB-231
cells were investigated.
Figure 13 depicts the effects of environment on either siRNA treated or untreated
cells stained for CD44+ and FoxO3a. For untreated cells there was no significant
difference between the mean intensity of CD44+ and the mean intensity of FoxO3a in
cells grown in 2D. There was a significant difference between the mean intensity of
CD44 and the mean intensity of FoxO3a in cells grown in a 3D environment. The mean
intensities of CD44+ between the untreated cells grown in either 2D or 3D environments
did not show a significant difference. The mean intensities of FoxO3a between the
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untreated cells grown in either 2D or 3D environments did not show a significant
difference. For siRNA treated cells there was no significant difference between the mean
intensity of CD44+ and the mean intensity of FoxO3a in cells grown in 2D. There was a
significant difference between the mean intensity of CD44+ and the mean intensity of
FoxO3a in cells grown in a 3D environment. The mean intensities of CD44+ between the
siRNA treated cells grown in either 2D or 3D environments did not show a significant
difference. The mean intensities of FoxO3a between the siRNA treated cells grown in
either 2D or 3D environments did not show a significant difference.
Figure 14 depicts the effects of environment on either siRNA treated or untreated
cells stained for Ki67 and FoxO3a. For untreated cells there was not a significant
difference between the mean intensity of Ki67 and the mean intensity of FoxO3a in cells
grown in 2D culture, but there was a significant difference between the mean intensity of
Ki67 and the mean intensity of FoxO3a in cells grown in 3D culture. There was no
significant difference in the mean intensities of Ki67 in untreated cells between 2D and
3D cell culture. There was a significant difference in the mean intensities of FoxO3a in
untreated cells between 2D and 3D cell culture. For treated cells there was not a
significant difference between the mean intensity of Ki67 and the mean intensity of
FoxO3a in cells grown in 2D culture. There was a significant difference between the
mean intensity of Ki67 and the mean intensity of FoxO3a in treated cells grown in 3D
culture. There was not a significant difference in the mean intensities of Ki67 in treated
cells grown in either 2D or 3D cell culture nor was there a significant difference in the
mean intensities of FoxO3a in treated cells grown in either 2D or 3D cell culture.
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Treatment
The effects of siRNA treatment on the expression of CD44+, Ki67, and FoxO3a in
MDA-MB-231 cells grown in either 2D or 3D cell culture were investigated.
Figure 15 depicts the effects of treatment on the stained CD44+ and FoxO3a cells
grow in either 2D or 3D cell culture. For cells grown in 2D culture there was no
significant difference between the mean intensity of CD44+ and the mean intensity of
FoxO3a in either the siRNA treated or untreated cells. There was no significant
difference in the mean intensities of CD44+ in siRNA treated and untreated cells or in the
mean intensities of FoxO3a in siRNA treated and untreated cells. For cells grown in 3D
culture there was a significant difference between the mean intensity of CD44+ and the
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mean intensity of FoxO3a in both cells untreated and treated with siRNA. There was not
a significant difference in the mean intensities of CD44+ between the treated and
untreated cells nor was there a significant difference in the mean intensities of FoxO3a
between the treated and untreated cells.
Figure 16 depicts the effects of treatment on the stained Ki67 and FoxO3a cells
grow in either 2D or 3D cell culture. For cells grown in 2D cell culture there was no
significant difference between the mean intensity of Ki67 and the mean intensity of
FoxO3a in either cells untreated or treated with siRNA. There were no significant
differences in the mean intensities of Ki67 between the treated or untreated cells. There
was no significant difference in the mean intensities of FoxO3a between the treated and
untreated cells. For cells grown in 3D cell culture there was a significant difference
between the mean intensity of Ki67 and the mean intensity of FoxO3a in both the treated
and untreated cells. The mean intensities of CD44+ between treated and untreated cells
were not significantly different. There was not a significant difference in the mean
intensities of FoxO3a between the treated and untreated cells.
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Proliferation Assay
The effects of cell culture environment on the proliferation of MDA-MB-231
cells at different incubation times was investigated.
Figure 17 depicts the proliferation over time of the cells in either 2D or 3D cell
culture with controls taken into account. Overall there was no significant difference of
proliferation between 2D and 3D cell culture environments over time (P=0.5508).
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Wound Healing Assay
A set of wound healing assays were performed to investigate the motility of
MDA-MB-231 cells over time.
Figure 18 depicts the percentage of the wound area taken up by migrating cells
over time. The p-value from the ANOVA of the one-way analysis of the percent area
covered over time (P<0.0001) demonstrated that the average percent area was not equal
at the different incubation times upholding that there was a change in percent area over
time, which was to be expected.
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CHAPTER FIVE
DISCUSSION

The results demonstrate changes in the cell culture environment can have an
effect on the expression of certain proteins in TNBC cells. The results from the first set
of experiments regarding the expression of CD44+, Ki67, and FoxO3a in three types of
TNBC cell lines demonstrate FoxO3a expressions varied between the 2D and 3D cell
culture environments. Among the three cell lines there was a common trend in cells
stained with Ki67 and FoxO3a. As indicated in figure B there was an increase of FoxO3a
expression in the 3D cell culture environment verses the 2D environment. Figure B
demonstrates these increases in FoxO3a expression were significantly different indicating
environment does have an effect on the expression of FoxO3a in cultured TNBC cells.
The MDA-MB-157 cells stained for CD44+ and FoxO3a demonstrated a significant
increase of FoxO3a expression in 3D cultured cells versus the 2D cultured cells as
displayed in figure A. The BT-549 and MDA-MB-231 cells did indicate an increase of
FoxO3a expression in the cells cultured in 3D versus 2D as demonstrated in figure A, but
these were not significant enough to conclude if environment had an effect on expression
of FoxO3a with these staining regimens. The images used for analysis demonstrated a
difference in the appearance of FoxO3a expression between the 2D and 3D cell culture
environments. Figure 1 demonstrated this change in appearance in BT-549 cells. There
was a difference in appearance of FoxO3a expression in the images of the cells stained
for Ki67 and FoxO3a. Compared to the image of the BT-549 cells cultured in the 2D
environment, the cells cultured in the 3D cell culture indicated a higher amount of red
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immunofluorescence, which represented the FoxO3a expression, in the cells. This
difference in FoxO3a appearance in the analyzed images could be observed in the MDAMB-231 cells represented in figure 7. The cells stained for Ki67 and FoxO3a and the
cells stained for CD44+ and FoxO3a indicated an increased red immunofluorescence in
the images of the 3D cultured cells. The images in figure 4 representing the analyzed
images of the MDA-MB-157 cell line there did not appear to be much of a difference in
the appearance of FoxO3a between any of the images. As demonstrated in figures A and
B there was a significant difference in the expression of FoxO3a between the 2D and 3D
cell culture environments with both of the staining regimens. There may be a number of
factors could influence the outcome; one being the program CellProfiler detected more
color intensity compared to that perceived with the naked eye. Another observation
determined from the images of the BT-549 and MDA-MB-231 cells was the increase of
FoxO3a expression in the 3D cell culture environment was primarily located in the
cytoplasm of the cells. This increase of cytoplasmic FoxO3a could be due to a change in
the shape of the cells cultured in the 3D environment. Another speculation is the increase
in cytoplasmic FoxO3a could be a result of the 3D cell culture environment having an
effect on the Akt activity of the cells. As previously discussed, the increase of Akt
activity in cells led to an increase in FoxO3a phosphorylation, which led to inactivation
of FoxO3a and an increase of inactive FoxO3a being shuttled out into the cytoplasm
(Zhang, et al., 2011). Since the 3D cell culture environment was used to mimic the tumor
environment cancer cells would encounter in tissue and since Akt is highly active in most
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cancers, these results could indicate the cells were demonstrating activities closer to in
vivo studies.
Another observation from the first set of experiments was the expression of
CD44+ or Ki67 did not vary between the cell culture environments in all three cell lines.
It was hypothesized expression levels would change because of the change in shape of
the cells between the 2D and 3D cell culture environment. It was presented that cells
cultured in a 3D environment would exhibit a better resemblance of cell shape observed
in tissue (Kim, 2005). As stated previously, this change in shape could explain the
increase of FoxO3a expression in 3D cultured cells. An increase of the cell surface
protein CD44+ in the cells cultured in the 3D environment was not observed as
demonstrated in figures A. As demonstrated in figures B there was not a significant
difference in the expression of Ki67 between the cell culture environments. At this point
in time it is unclear whether cell shape changes between a 2D and 3D cell culture
environment do affect the expression of proteins in TNBC cells.
An observation in regards to shape of cells and growth behavior realized in the
analyzed images in figure 1 was BT-549 cells grew closer together forming masses of
cells in the 3D cell culture environment. This growth behavior was not observed in the
2D cell culture of BT-549 cells. This observation could be compared to the results from
the experiments done by Debnath et al. in 2003. They discovered when growing the noncancerous breast cells MCF-10A in 3D cell culture the cells formed acini with hollow
lumens, a common characteristic of healthy breast cells in tissue. They did not observe
this same behavior in the traditional 2D cell culture environment (Debnath,
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Muthuswamy, & Brugge, 2003). This observation could help to understand the growth
behavior of TNBC cells and the importance of cell contact to an extracellular matrix
during tumor progression.
The results for both the BT-549 and MDA-MB-157 cell lines demonstrated a
significant difference of expression between CD44+ and FoxO3a in 3D cultured cells.
This same observation was detected in all three cell lines stained for Ki67 and FoxO3a in
the 3D cell culture environment. This was to be expected because CD44+, Ki67 and
FoxO3a are three different proteins and sharing similar expression levels was not the
primary focus of the study.
The results from the FoxO3a targeting siRNA treated MDA-MB-231 cell
experiments did not demonstrate as many conclusive results as the ones discussed above.
It was hypothesized a knockdown of FoxO3a would demonstrate a significant difference
in expression levels of FoxO3a between treated and untreated cells and similar to the
results from the first set of experiments the cell culture environment would have an effect
on FoxO3a expression. From the image of the western blot in figure 10 it was observed
the siRNA was able to knockdown FoxO3a, but only partially. The images in figures 11
and 12 illustrate a slight decrease in the amount of red immunofluorescence being
expressed in the cells in both culture environments and staining regimens, but again it
was not a complete knockdown of expression. This partial knockdown may explain the
absence of significant differences in the expression of FoxO3a between the treated and
untreated MDA-MB-231 cells. The partial knockdown could possibly even the lack of
significant difference between the cell culture environments. The data for the untreated
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cells were from the previous experiments so those results were not expected to change.
The only difference was due to a change in statistical analysis parameters, the expression
of FoxO3a was significantly different from CD44+ in the cells cultured in the 3D
environment for the siRNA analysis but not for the previous analysis. This change did
not affect the results previously stated cells under the CD44+ and FoxO3a staining
regimen did not indicate a significant difference in the expression of FoxO3a between
cell culture environments. This was one of the primary focuses of both the previous set
of experiments and the siRNA experiments.
The results for the siRNA treated cells stained for Ki67 and FoxO3a did not
indicate a difference in the expression of FoxO3a between the 2D and 3D cell culture
environments as demonstrated in figure 14. These results vary from the untreated cells
presented in figure 14, which exhibited a significant difference in the FoxO3a expression
between the cell culture environments. There was not a significant difference in the
expression of FoxO3a between the 2D and 3D cell culture environments in treated cells
stained for CD44+ and FoxO3a, which was observed in the untreated cells. Figure 15 and
16 demonstrated there was not a significant difference between the treated and untreated
in either cell culture environments and in both staining regimens, which could be
correlated with the partial knockdown of FoxO3a in the cells. As previously discussed,
in the first set of experiments there was not a significant difference in the expression of
CD44+ in the untreated cells in both cell culture environments as demonstrated in figure
13, nor was there a significant difference in CD44+ expression between the treated and
untreated cells as demonstrated if figures 15. This absence of change between the CD44+
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expressions could imply along with cell culture environment, FoxO3a does not have an
effect on the expression of CD44+ or possibly the motility of cancer cells during EMT.
Further studies would need to be conducted to make more definitive conclusions. A
decrease in the expression of Ki67 in siRNA treated cells grown in the 3D cell culture
environments was observed. This change in expression was not significant between
either the siRNA treated cells in the different cell culture environments, or between the
treated and untreated cells. The change in expression was most likely due to the cells
being treated with the siRNA had to be incubated with serum free media thus decreasing
proliferation activity and Ki67 activity whereas the untreated cells were always incubated
with supplemented media containing serum. There could be a decrease in FoxO3a
expression that affects Ki67 expression as well. The study by Marlow et al. demonstrated
the overexpression of FoxO3a led to an increase in proliferation rates by inducing cyclin
A in the highly invasive anaplastic thyroid cancer. Further studies would need to be
conducted in order to conclude whether or not FoxO3a has a role in cell proliferation in
TNBC cells.
The proliferation assays of MDA-MB-231 cells demonstrated changing the cell
culture did not affect the proliferation rate of cells over time. These results can be
correlated with the results from the first set of experiments comparing expression levels
of Ki67 between the three cell lines cultured in both of the cell culture environments. As
previously discussed, the proliferation marker did not change expression levels between
the 2D and 3D cell culture environments in any of the three cell lines. This could lead to
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the hypothesis that the proliferation activity in TNBC cells should not change between
cells grown in different cell culture environments.
The wound healing assays demonstrated percentage of the wound area covered by
MDA-MB-231 cells increases over time as was hypothesized. This assay could only be
performed in a 2D cell culture environment because when scraping a wound area in the
3D cell culture membrane would not only result in removing cells, but the membrane as
well, leaving a 2D wound area, but the cells left on the slides would be in a 3D
environment. Performing a wound healing assay like the one used in this experiment is
cost effective and straightforward, but there was a large margin of error and replicating
the results in a 3D environment was not very feasible. The wounds were individually
created with a pipet tip and they were not always uniform, which could have led to errors
between each slide. The scraping method was not always a clean method because pieces
of cells were sometimes left in the wound area, which could have altered some results.
The wounds were large and a lower magnification had to be used to capture both the
wound area and surrounding cells. Analyzing the images for the expression of CD44+,
Ki67, and FoxO3a similar to the first experiments was difficult because there were more
cells to measure and increase background noise from the cell debris left by the scraping
of the cells. Further studies with a more uniform wound producing method such as
wound healing kits or other migration techniques would need to be used to obtain more
definitive results, especially for studies incorporating a 3D cell culture environment.
Conclusion
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For this research, it was hypothesized a change in the cell culture environment
would affect the expression of one or all of the proteins, CD44+, Ki67, and FoxO3a in
TNBC. The results of the protein expression in the three TNBC cells indicated of all the
proteins FoxO3a was the only one to demonstrate a cell culture environment effect on the
expression levels. These results could assist in future studies of TNBC cells and their
behavior in a 3D cell culture environment and in determining the role of FoxO3a in
TNBC cells. Future studies investigating the high amount of FoxO3a expression in the
cytoplasm in cells cultured in a 3D environment could be performed. One study in
particular could be done to investigate the activity of Akt in TNBC cells in both a 2D and
3D cell culture environment to determine if this has an effect on the FoxO3a expression.
The results from the FoxO3a targeting siRNA treated MDA-MB-231 cells were
inconclusive due the incomplete knocked down of FoxO3a. Future studies using either a
custom made siRNA sequence or another type of FoxO3a inhibitor could be used to
determine if FoxO3a could affect CD44+ and Ki67 expression. Studies investigating the
affect of knocking down FoxO3a in TNBC could be performed to determine if FoxO3a
has a role in proliferation and migration of cancer cells.
The proliferation and the wound healing assay results are only preliminary;
nevertheless these results can serve as a platform for future proliferation and migration
studies in TNBC cells. These studies could be optimized to determine the role of FoxO3a
and the EMT and MET activity of TNBC cells.
All of these results can assist in future cell culture studies and have the potential
to assist in the transition of TNBC studies in FoxO3a and EMT/MET to tissue and
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perhaps even in vivo studies. Being able to demonstrate EMT and MET activity in cell
culture and repeating in vivo could further strengthen the evidence proving these cellular
processes occur in cancer cells. Furthermore, these types of studies could assist in
reaching the ultimate goal of developing improved therapies for those types of cancers
such as TNBC that are difficult to treat with traditional therapies.
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Appendix A
Compilation of the Three Cell Line Figures with CD44+ and FoxO3a
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Appendix B
Compilation of the Three Cell Lines Figures with Ki67 and FoxO3a
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